Adamis Pharmaceuticals Corp. (ADMP) Shares Down 3.3%
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) dropped 3.3% during mid-day trading on Monday . The stock traded as low as $2.87 and last traded at $2.92, with a volume of 113,451 shares trading hands. The stock had previously closed at $3.02.
Separately, Maxim Group raised their price objective on Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, March 29th.
The company’s market capitalization is $44.40 million. The stock’s 50 day moving average is $3.10 and its 200-day moving average is $5.56.
In related news, SVP David J. Marguglio sold 4,000 shares of Adamis Pharmaceuticals Corp. stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.08, for a total transaction of $32,320.00. Following the transaction, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David J. Marguglio sold 4,860 shares of Adamis Pharmaceuticals Corp. stock in a transaction on Monday, May 9th. The shares were sold at an average price of $10.00, for a total transaction of $48,600.00. Following the transaction, the senior vice president now owns 106,227 shares in the company, valued at approximately $1,062,270. The disclosure for this sale can be found here.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.